Connect with us

Featured

Brewbilt Brewing Co (OTCMKTS: BRBL) Steady Run Northbound as Emerging California Craft Beer Brewer Gets into Albertsons’ Safeway Stores

Published

on

Brewbilt Brewing Co (OTCMKTS: BRBL) is making an explosive move up the charts since reversing off $0.0027 lows earlier this year. Still trading at a tiny $1.7 million market valuation the Company is starting to get noticed as it has built a quality commercial brewery, began marketing and production of its core craft beers, launched them in July and is now on the shelves of the two largest grocery store chains in the world including Albertsons’ Safeway Stores. The Company recently stated that based upon craft brewery trends and recent events with the largest grocery store chains the Company can target $20M in annual revenue. 

In a recently press release CEO Jeff Lewis stated: “We had a meeting this week to discuss an opportunity with a large California based entertainment and hospitality company that owns and operates a combination of over 100 hotels, restaurants, and lounges. There is consideration in franchising the BrewBilt Brewing brand as the Company is now being recognized for its German-inspired beers using traditional techniques and California craft malts and other local ingredients. BrewBilt Brewing Company has very good ratings on the popular craft beer rating site Untappd.com.” 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Brewbilt Brewing Co (OTCMKTS: BRBL) Located in the Sierra Foothills of Northern California, BrewBilt Brewing Company produces its own line of premium craft beers. BrewBilt Brewing grew out of BrewBilt Manufacturing Inc., an iconic company that has been handcrafting custom breweries and fermentation systems since 2014. BrewBilt Brewing’s production staff consists of industry veterans who use high quality brewing equipment and ingredients to deliver outstanding craft beer to California and beyond. BrewBilt Brewing also offers contract brewing services for other breweries in need of additional capacity as well as private label ales for restaurants and bars desiring their own house beer. 

The company is quickly being recognized for its German inspired beers using traditional techniques and California craft malts and other local ingredients. BrewBilt Brewing Company has very good ratings on the popular craft beer rating site Untappd.com. The Company has a Type 23 License in the State of California which allows for up to an annual production of 60,000 BBL of craft beer. This equates to $36,000,000 in revenue. The Company plans to seek a Type 1 License which will allow for an unlimited production amount. 

BrewBilt Brewing has its brewing facility in Grass Valley, California. This facility was leased by BrewBilt and was upgraded with substantial tenant improvements to include a 20 BBL brewhouse, 20 and 40 BBL fermentation tanks, cold-storage space, and a state-of-the-art canning line. In July of 2021, BrewBilt took the opportunity to expand again by leasing additional space adjacent to the original lease. BrewBilt Brewing LLC received its Brewers Notice from the Alcohol and Tobacco Tax and Trade Bureau (TTB). and recently secured a Type 23 Small Beer Manufacturer license from the California Alcoholic Beverage Control Board (ABC).  

The Company’s subsidiary the Satel Group is a premier provider of DirecTV to high-rise apartments, condominiums and large commercial office buildings in the San Francisco metropolitan area and offers Internet services across the Bay Area. 

To Find out the inside Scoop on BRBL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BRBL

In a recent update CEO Jef Lewis stated: “BrewBilt Brewing Company is one of the fastest expanding new brewers in the USA. Within the past 12 months the Company built a quality commercial brewery, began marketing and production of its core craft beers, launched them in July and is now on the shelves of the two largest grocery store chains in the world. In the history of brewing, no brewery has expanded into big-box distribution within a three-month period from its first production line. We have on board a seasoned team of professionals who have a successful track record and who are well known in the industry that bring the company decades of experience. I plan on expanding on the details of our growth and who we are over the next 60 days. It is important to me that the public and our shareholders are a part of our story. Without them, we would not be here today.” 

On November 22 BRBL announced based upon craft brewery trends and recent events with the largest grocery store chains the Company can target $20M in annual revenue. Craft brewery companies and startups provide solid data that indicates positive and aggressive growth based on their funding history, investment activities, and acquisition trends. BrewBilt Brewing’s growth trends in the past five months are steady and strong. 

CEO Jef Lewis stated, “We are now proud to be an Albertsons/Safeway and Grocery Outlet craft beer supplier. Our first sales began on July 19, 2022, less than five months ago. Other well-known breweries performed very well in their first two years of production such as the sales of Stone Brewing Company whose beers topped $15 million in the first 12 months of sales. Founders Brewery saw 59.7% growth with sales of over $18 million in their first 24 months. Bell’s earned 25.9% growth in the same year, with Americans spending $18.9 million on the brewer’s beers. Wisconsin-based New Glarus also grew in 2017, albeit at a more modest level of 7.9%, with a value of $19.8 million. Elysian, meanwhile, sold $24.1 million worth of pale ales and IPAs last year, a boost of 80.9%. Sweetwater Brewing Company, founded in Atlanta, Georgia in 1997, witnessed 17% growth over the same period, with sales totaling $25.5 million. New Belgium’s sales stayed fairly steady with a modest rise of 1.3% and sales were valued at $44.6 million. We had a meeting this week to discuss an opportunity with a large California based entertainment and hospitality company that owns and operates a combination of over 100 hotels, restaurants, and lounges. There is consideration in franchising the BrewBilt Brewing brand as the Company is now being recognized for its German-inspired beers using traditional techniques and California craft malts and other local ingredients. BrewBilt Brewing Company has very good ratings on the popular craft beer rating site Untappd.com.” 

  For More on BRBL Subscribe Right Now!

Currently trading at a $1.7 million market valuation BRBL os is 117,698,070 with less than 30 million shares in the float. The Company has $1.9 million in assets vs. $4.6 million in liabilities and minimum revenues to date. BRBL is an exciting story developing in small caps; still trading at a tiny valuation the Company is making big moves since launching its commercial brewery Grass Valley, California. Brewbilt is quickly becoming recognized for its German-inspired beers using traditional techniques and California craft malts and other local ingredients. BrewBilt Brewing Company has very good ratings and is making moves in an estimated $10 billion annual California craft beer market. We will be updating on BRBL so make sure you are subscribed to microcapdaily.com.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in BRBL either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.